Reducing Donor Specific HLA Antibody Strength in Maintenance Kidney Transplant Recipients (DSA Study)
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2010 |
| End Date: | January 2015 |
An Exploratory, Open-Label, Single Center Study to Assess the Efficacy and Dose Titration of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Reducing Donor Specific HLA Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients
The purpose of this study is to demonstrate that increased dosages of mycophenolic acid in
maintenance kidney transplant recipients may cause a reduction in donor-specific antibodies.
The development of donor-specific HLA antibody (DSA) post-transplant has been associated
with chronic rejection and graft failure. Mycophenolic Acid (MPA) is thought to be the key
drug preventing both cellular and antibody mediated rejections. Several studies have shown
that recipients receiving an optimal dose of MPA have fewer antibody mediated rejections and
may require a lower dose of calcineurin inhibitors and/or corticosteroids thus reducing side
effects and extending graft survival.
We found this trial at
1
site
Click here to add this to my saved trials
